A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
Latest Information Update: 19 Jun 2025
At a glance
- Drugs Felzartamab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TRANSCEND
- Sponsors Human Immunology Biosciences
Most Recent Events
- 11 Mar 2025 According to a Biogen media release, the company announced initiation of dosing in this trial. As part of the initiation of the Phase 3 trial for felzartamab, MorphoSys will earn a one-time milestone payment of $35 million from Biogen.
- 09 Dec 2024 Status changed from not yet recruiting to recruiting.
- 18 Nov 2024 Status changed from planning to not yet recruiting.